US FDA approves Boehringer’s Hernexeos for HER2-positive NSCLC
Hernexeos, a tyrosine kinase inhibitor that selectively targets HER2, is the first oral targeted therapy approved for HER2-mutant advanced NSCLC.
Analysis
View MoreThe ultimate hub for fine and speciality chemicals
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery